Osteoporosis – Landscape & Forecast – Disease Landscape & Forecast
With an increasing prevalence owing to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers, increasing uptake of Evenity, and drug launches will support the market through 2031. However, market growth will be tempered by the generic erosion of key brands. The relatively low diagnosis and drug-treatment rates for osteoporosis, owing to the asymptomatic nature of the disease, will also continue to hold back the market. Driven largely by their widespread generic availability and strong physician familiarity, bisphosphonates continue to dominate first-line treatment, creating a significant barrier to uptake for novel therapies. Emerging therapies will need to demonstrate a significant risk-clinical benefit balance, at a competitive price, to challenge the bisphosphonates as first-line treatments. Therefore, most emerging therapies will compete for use as second- or third-line treatments.
Questions Answered:
- What are the drivers and constraints in the osteoporosis market, and how will the market evolve over the forecast period?
- How has Amgen / UCB’s Evenity been integrated into the U.S., U.K., and German treatment algorithm, and how will it be positioned in Japan and rest of the European market?
- What do thought leaders think of the emerging therapies and the current treatment options and practices? How will uptake of the emerging agents impact current market-leading therapies?
- What impact will the generic entries of key brands, such as Prolia, have on the osteoporosis market?
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts.
Epidemiology: Prevalence of osteoporosis by country, with diagnosed and drug-treated population.
Emerging therapies: Phase III: 1 drug; Phase II: 1 drug. Coverage of select Phase I products.
Key drugs: Denosumab, teriparatide, abaloparatide SC, abaloparatide TD, EB-613, alendronate, romosozumab, raloxifene.
Market forecast features: 10-year, annualized, drug-level sales and patient share of key osteoporosis therapies through 2031, segmented by brands / generics.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Osteoporosis - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Osteoporosis - Key findings - February 2023
- Key Updates
- September 2023
- June 2023
- February 2023
- Q4 2022
- November 2022
- October 2022
- Q3 2022
- July 2022
- Q2 2022
- June 2022
- Market outlook
- Key findings
- Market share of osteoporosis drug classes: 2021
- Market share of osteoporosis drug classes: 2031
- Osteoporosis SWOT analysis
- Market drivers and constraints
- What factors are driving the market for osteoporosis?
- What factors are constraining the market for osteoporosis?
- Market sales of osteoporosis drugs in the major markets: 2021-2031
- Patient share of osteoporosis drugs in the major markets: 2021-2031
- Drug-class-specific trends
- Patient share of bisphosphonates in osteoporosis in the United States: 2021-2031
- Patient share of bisphosphonates in osteoporosis in Europe: 2021-2031
- Patient share of bisphosphonates in osteoporosis in Japan: 2021-2031
- Patient share of SERMs in osteoporosis in the major markets: 2021-2031
- Patient share of parathyroid hormone analogues in osteoporosis in the United States: 2021-2031
- Patient share of parathyroid hormone analogues in osteoporosis in Europe: 2021-2031
- Patient share of parathyroid hormone analogues in osteoporosis in Japan: 2021-2031
- Patient share of the RANKL inhibitors in osteoporosis in the United States: 2021-2031
- Patient share of the RANKL inhibitors in osteoporosis in Europe: 2021-2031
- Patient share of the RANKL inhibitors in osteoporosis in Japan: 2021-2031
- Patient share of sclerostin inhibitors in osteoporosis in the major markets: 2021-2031
- Patient share of calcitonins, hormonal agents, and other therapies to treat osteoporosis in the major markets: 2021-2031
- Key findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and pathophysiology
- Disease overview
- Etiology
- Primary osteoporosis
- Secondary osteoporosis
- Causes of secondary osteoporosis
- Risk factors
- Risk factors for developing osteoporosis
- Osteoporosis: a risk factor for fractures
- Risk factors for fracture
- Key pathways and drug targets
- Anatomy
- Bone remodeling and turnover
- Immunologic effects
- Drug targets
- Summary of osteoporosis drug targets and their mechanisms of action
- Drug targets in the bone remodeling process
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Total prevalent cases of osteoporosis (NBHA definition): 2021-2031 (thousands)
- Total prevalent cases of osteoporosis (NBHA definition) among males: 2021-2031 (thousands)
- Total prevalent cases of osteoporosis (NBHA definition) among females: 2021-2031 (thousands)
- Total prevalent cases of osteoporosis (WHO definition): 2021-2031 (thousands)
- Total prevalent cases of osteoporosis (WHO definition) among males: 2021-2031 (thousands)
- Total prevalent cases of osteoporosis (WHO definition) among females: 2021-2031 (thousands)
- Disease definition
- Total prevalence of people at high risk of a hip fracture or major osteoporotic fracture: 2021-2031 (thousands)
- Total prevalent cases of men at high risk of a hip fracture or major osteoporotic fracture: 2021-2031 (thousands)
- Total prevalent cases of females at high risk of a hip fracture or major osteoporotic fracture: 2021-2031 (thousands)
- Diagnosed prevalent cases of osteoporosis in the mature markets (thousands): 2021-2031
- Drug-treated prevalent cases of osteoporosis in the mature markets (thousands): 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for osteoporosis
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for osteoporosis
- Current treatments used for osteoporosis
- Market events impacting the use of key current therapies in osteoporosis
- Advantages and disadvantages of bisphosphonates
- Expert insight: bisphosphonates
- Advantages and disadvantages of selective estrogen receptor modulators
- Expert insight: selective estrogen receptor modulators
- Advantages and disadvantages of teriparatide
- Key results from select clinical trials investigating teriparatide for the treatment of osteoporosis
- Expert insight: teriparatide
- Advantages and disadvantages of abaloparatide SC
- Key ongoing clinical trials investigating abaloparatide for the treatment of osteoporosis
- Expert insight: abaloparatide SC
- Key ongoing clinical trials of denosumab in the treatment of osteoporosis
- Advantages and disadvantages of romosozumab
- Expert insight: romosozumab
- Advantages and disadvantages of calcitonins
- Expert insight: calcitonins
- Advantages and disadvantages of hormone replacement therapy
- Expert insight: hormone replacement therapy
- Medical practice
- Overview
- Factors influencing drug selection in osteoporosis
- Region-specific treatment practices
- Treatment decision tree for osteoporosis: United States
- Treatment decision tree for osteoporosis: Europe
- Treatment decision tree for osteoporosis: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in osteoporosis
- Top unmet needs in osteoporosis: current and future attainment
- Expert insight: unmet need in osteoporosis
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Estimated launch dates of key emerging therapies for the treatment of osteoporosis
- EB-613
- Key results from select clinical trials investigating EB-613 for the treatment of osteoporosis
- Analysis of the clinical development program for EB-613
- Expert insight: EB-613
- Expectations for launch and sales opportunity of EB-613 in osteoporosis
- Early-phase pipeline analysis
- Select compounds in early-phase development for osteoporosis
- Key discontinuations and failures in osteoporosis
- Expert insight: osteoporosis therapy development
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in osteoporosis: United States
- General reimbursement environment: United States
- Key market access considerations in osteoporosis: EU5
- General reimbursement environment: EU5
- Key market access considerations in osteoporosis: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviation
- Osteoporosis bibliography
- Supplemental epidemiology bibliography
- Key findings
Manasa Kadagathur, M.S. (Pharm.), Ph.D., Associate analyst, Cardiovascular, Metabolic, Renal, and Hematologic Disorders. Dr. Kadagathur has authored reports on osteoporosis and nonalcoholic steatohepatitis (NASH). She holds an M.S. (Pharm.) degree in medicinal chemistry from the National Institute of Pharmaceutical Education and Research (NIPER) in S.A.S. Nagar, India, and a bachelor’s degree in pharmacy from Jawaharlal Nehru Technological University in Hyderabad, India. She earned her Ph.D. in medicinal chemistry from NIPER in Hyderabad, India.